NASDAQ:CYCN   Cyclerion Therapeutics, Inc.
No news on April 9th and no filings either. But CYCN jumped to $3.10 after-hours. The initial pop began during the final hours of the afternoon session with a big volume spike that pushed the stock back above $3 for the first time, to the upside, in a few weeks.

A MELAS Phase 2a study is underway. So the market could be waiting for any updated data to shed light on progress. As it stands right now, top-line data is expected in “mid-2021.” There’s also a Phase 2a study on patients who have Alzheimer’s disease with vascular pathology. The company is expected to initiate this in “mid-2021” as well. Does Friday’s aftermarket momentum have anything to do with its current pipeline? We’ll have to see how Monday begins. In the meantime, CYCN could be one of the penny stocks to watch this week.

Quote Source: Best Penny Stocks To Buy Right Now? 3 For This Week’s Watch List

免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。